Probiotics are live microorganisms, which confer health benefits on host when administered in adequate amounts. Probiotics exert their beneficial effects by maintenance flora healthy, enhancement of mucosal barrier integrity and modulation of immune responses. Antimicrobial substances including bacteriocins, hydrogen peroxide, organic acids, and short-chain fatty acids (SCFAs) produced by probiotics allow them to inhibit mucosal and epithelial adherence of pathogens and compete for limiting resources, thus suppress the growth of bacterial and fungal pathogens. Probiotics effect the colonization of fungal pathogen Candida to host surfaces, suppress Candida growth and biofilm development in vitro. Clinical results have shown that some probiotics can reduce oral, vaginal, and enteric colonization of Candida, alleviate clinical signs and symptoms, and potentially reduce the incidence of invasive fungal infection. Therefore, probiotics may be potential antifungals for prevention and treatment of candidiasis.
Introduction
Probiotics are "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host," which was defined by the Food and Drug Organization of the United Nations (FAO) and World Health Organization (WHO) [1] [2] [3] . Probiotics should have some fundamental characteristics, such as human origin, nonpathogenic in nature, resistance to destruction by technical processing, acid and bile tolerances, adequate adherence and colonization on epithelial surfaces, antagonistic activity against pathogens, regulation of immune response, and influence human metabolic activities [4] [5] [6] [7] .
Bacteria belonging to the genera Lactobacillus and Bifidobacterium are the most frequently used probiotics. Besides, Enterococcus, Streptococcus, Saccharomyces, and Bacillus are also commonly used probiotics (representative species are listed in Table 1 ). The administration of probiotics has been confirmed as an alternative biological approach to combat bacterial and fungal pathogens in the oral cavity, GI tract, and urogenital system [4, 5, [7] [8] [9] [10] [11] [12] [13] [14] . It has been reported that probiotics could reduce Candida, which cause fungal infections in different organ systems of the human body and prevent bacterial infectious diseases [9, 10, 15] . Probiotics were capable of preventing cancers [16] , modulating blood pressure [17, 18] , and repressing cholesterol levels [19] . Recently, species of Akkermansia muciniphila, Eubacterium hallii, and Faecalibacterium prausnitzii are identified as new potential probiotics because of their great benefits to the microbial metabolic networks and human health, especially the effects on correcting the imbalance of gut microbiota composition [7, [20] [21] [22] . A combination of probiotics with traditional treatment has been thought to be a potential approach for treatment of certain diseases.
It is noteworthy that health benefits of probiotic bacteria are strain specific, which cannot be generalized to other strains, not even the same species, although some properties may be common for different strains because of the similarities in the metabolism of ecological functionality [5, 6] . Thus, the selection of certain probiotics for therapeutic purposes should be targeted for specific pathogens. Probiotics effects are dose specific [5, 6] . It has been suggested that a daily intake of 10 6 -10 9 colony-forming units (CFUs) of probiotic microorganisms is the minimum effective dose for therapeutic purposes [5, 6, 8] .
A number of probiotics are currently commercially available, and they have been categorized into single-strain or multi-strain/multispecies products [7, 23, 24] . Multi-strain/multispecies probiotics exhibited better effects than single-strain probiotics. 
Probiotics -Current Knowledge and Future Prospects
Bacteriocins are ribosomally synthesized antimicrobial peptides, which have broad spectrum of inhibitory effect against Gram-positive and Gram-negative bacteria, viruses, and fungi [47] [48] [49] [50] . L. plantarum 2.9, a bacteriocinogenic strain, inhibited a set of foodborne pathogens including B. cereus, E. coli O157:H7, and S. enterica [51] . Bacteriocin-producing strains identified in our lab, e.g., L. plantarum ZJ316, L. plantarum LZ95, L. plantarum ZJ008, and L. plantarum ZJ005, showed antimicrobial activity against various pathogens in vitro such as S. aureus, E. coli, S. enterica, L. monocytogenes, and C. albicans [42, [52] [53] [54] .
Enhancement of mucosal barrier integrity
Probiotics have been shown to improve barrier function and the mechanisms of barrier function including alteration of tight junction protein expression and/or localization, induction of mucus secretion, increased production of cytoprotective molecules such as heat-shock proteins, inhibition of apoptosis of epithelial cells, and promoting cell survival [29, 55, 56] . They compete with pathogens and prevent their invasion through the epithelium by the ability of adherence to the intestinal epithelium and mucus. L. plantarum has been shown to enhance mucosal barrier by adhering to the mucosal membrane and reducing Gram-negative bacteria [29] . Probiotics also compete for limiting resources, thus suppressing the growth of bacterial and fungal pathogens. The probiotic E. coli Nissle 1917 is able to effectively take up multiple limited environmental irons and simultaneously competitively inhibit the growth of other intestinal microbes and pathogens [57] .
Furthermore, butyrate, a short-chain fatty acid (SCFA), could reduce bacterial translocation, improve the organization of tight junctions, modulate intestinal motility in addition to being an energy source for colonocytes, and maintain the integrity of the intestinal epithelium [29-31, 58-60]. E. hallii is an important anaerobic butyrate producer resident in our gut, which influences the intestinal metabolic balance and enhances the host-gut microbiota homeostasis [61] . Thus, the administration of probiotics with butyrate-producing bacteria, in particular, could be an effective way to achieve health benefits.
Immune modulation
Probiotics are reported to enhance phagocytic activity of granulocytes and cytokine excretion in lymphocytes, increase immunoglobulin-secreting cells, and attenuate inflammasome activation. They are able to affect cells involved in immune responses, including epithelial cells, dendritic cells (DCs), T cells, regulatory T (Treg) cells, monocytes/macrophages, immunoglobulin A (IgA)-producing B cells, and natural killer cells [62, 63] .
Probiotic bacteria have an effect on intestinal DCs, which have the ability to recognize and respond to different bacteria by linking the innate immune system to the adaptive immune response and to develop T-and B-cell responses. Badia et al. found that the immunomodulatory role of S. boulardii in the DCs prior to infection was related to the upregulation of tumor necrosis factor alpha (TNFα) and C─C chemokine receptor type 7 mRNAs, which might make the DCs more effective in antagonizing bacteria [64, 65] . Smith et al. reported that S. boulardii stimulated the production of cytokines TNFα, IL-1, IL-12, IL-6, and IL-10 in DCs and also induced high levels of costimulatory molecules CD80 and CD86, thus modulated the immune system and led to an efficient clearing of enteropathogenic bacteria from the blood stream coupled with a faster cytokine response [65, 66] .
Probiotics also influence intestinal epithelial cells through interaction with Toll-like receptors (TLRs) and downregulate the expression of NF-κB and proinflammatory cytokines [67, 68] . This effect is supported by the following studies: the supernatant of probiotic Faecalibacterium prausnitzii inhibited the NF-κB pathway in vitro and in vivo and showed protective effects in different models such as dinitrobenzene sulfate (DNBS)-induced colitis model and dextran sodium sulfate (DSS)-induced colitis [69] ; the probiotic strain L. rhamnosus GG prevented cytokine-induced apoptosis in intestinal epithelial cells [70] ; and L. rhamnosus GR-1 reduced the adhesion of E. coli by promoting TLR2 and NOD1 synergism and attenuating ASCindependent NLRP3 inflammasome activation [71] .
Probiotic as antifungals for prevention and treatment of candidiasis
Candida is an opportunistic pathogen, causing mucosal infections including infections in the oral cavity, oropharynx, esophagus, and vagina, and potentially life-threatening systemic candidiasis. Candida albicans is the most common fungal pathogen in humans responsible for causing superficial as well as deep invasive candidiasis, which are essentially caused by
Candida biofilms attached to body surfaces. Other Candida species such as Candida tropicalis, Candida guilliermondii, Candida krusei, and Candida glabrata are less frequently isolated in healthy and diseased humans [72] [73] [74] . Probiotics are known to reduce Candida infection in different organs and are generally considered to be beneficial for overall health. They appear to assist the host combat the pathogen by suppressing filamentation formation and reducing biofilm development, the mechanism of which may be related to expression of genes associated with biofilm formation and filamentation in Candida species. In vitro and in vivo studies have demonstrated the role of probiotics in the prevention of Candida colonization and invasive candidiasis [38, [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] .
In vitro evidences: probiotics in prevention/treatment of Candida infections
Several in vitro studies have addressed the antifungal effects of probiotics against Candida isolated from the human oral cavity, GI tract, and genitourinary tract [77-81, 86, 87] . The probiotics that have been investigated against Candida species include Lactobacillus (e.g., L. rhamnosus, L. plantarum, L. fermentum, L. acidophilus, L. paracasei, L. johnsonii, and L. salivarius), Bifidobacterium (e.g., B. bifidum and B. infantis), Saccharomyces (e.g., S. boulardii), and Streptococcus (e.g., S. thermophilus). Table 3 shows candidacidal activity of probiotic strains in different studies. C. albicans appears to be more susceptible to the antifungal effect of Lactobacillus than C. pseudotropicalis [81] , and the probiotics exhibited growth inhibitory activities against C. glabrata, C. krusei, and C. parapsilosis [79, 87] . [87] . Therefore, it is likely that the antimicrobial molecules, organic acids, and Н 2 О 2 produced by probiotic are major factors to limit growth of fungal pathogen Candida. 
In vivo evidences: probiotics in prevention/treatment of Candida infections
In vivo studies, especially RCTs, have also been performed to substantiate the antifungal activity of probiotics in humans. These studies mostly focus on the sites of oral cavity, GI tract, and urogenital tract, which are susceptible to Candida infections ( Table 3) .
The elderly are a group particularly susceptible to oral candidiasis, because of frequent usage of dentures, hyposalivation, and their weakened immune status. Researches by Hatakka et al. and Kraft-Bodi et al. have shown that the daily consumption of food with L. reuteri DSM17938, L. reuteri ATCC PTA 5289, and L. rhamnosus GG ATCC 53103 significantly reduced the high yeast counts in saliva and biofilms in the elderly [76, 85] . The removal of biofilms by the use of probiotics that reduce the oral burden of Candida could play a major role in preventing oral candidiasis in denture wearers.
For the urogenital tract, chronic vulvovaginal candidiasis (VVC) is the most common candidiasis disease and impacts the life quality of thousands of women around the world. Researches on the effect of probiotics in the treatment and prophylaxis of VVC have been performed [ Table 3 . Probiotics in prevention/treatment of Candida infections.
Probiotics -Current Knowledge and Future Prospects
GR-1 and L. reuteri RC-14 significantly reduced the presence of Candida and therefore reduced the vaginal discharge, itching, and/or burning vaginal feeling, dyspareunia, and/or dysuria [82] .
For the GI tract, Candida species are common inhabitants of GI tract. Dysbiosis of GI tract may lead to candidal overgrowth and possible invasive infections, especially in infants. Hence, immunocompromised children, especially preterm neonates with low birth weight, have been the target population of a large number of studies to evaluate the prevention or/and L. acidophilus, B. lactis, B. longum, and B. bifidum reduced enteral fungal colonization and invasive fungal sepsis in 112 preterm neonates (gestational age < 37 wk and birth weight < 2500 g) [75] .
Together, both the laboratory studies and clinical studies showed that probiotics could prevent Candida colonization by inhibiting adhesion, filamentation, and biofilm formation, and therefore supplementation of probiotics could be a potential approach for reducing Candida colonization and invasive candidiasis.
Safety of probiotics
Although most commercially available probiotic strains are generally regarded as safe and none of the clinical studies mentioned above were reported to have adverse effects directly related to probiotics, there are some concerns regarding the safety of probiotics, including potential of bacteremia and/or endocarditis occurrence, toxicity to the gastrointestinal tract, and transfer of antibiotic resistance [4] .
Potential of bacteremia and/or endocarditis occurrence
Lactic acid bacteria, including Bifidobacterium, have been reported to cause bacteremia as well as endocarditis [88] [89] [90] [91] [92] . Cannon et al. described that L. rhamnosus caused liver abscess, lactobacillemia, and infective endocarditis in a few case studies, and also the occurrence of Lactobacillus sepsis was directly linked with the ingestion of probiotic supplements, especially among immunocompromised patients and those with endocarditis [89] . Kunz 
Toxicity to the gastrointestinal tract
The role of probiotics on gastrointestinal physiology suggests a theoretical possibility that the production of metabolites might be undesirable and also might lead to malabsorption due to deconjugation of bile salts. These might increase the risk of colon cancer; however, there is no epidemiologic or clinical evidence to support this hypothesis [94, 95] .
Transfer of antibiotic resistance
Another major safety concern of theoretical importance is genetic transfer of antibiotic resistance from probiotic strains to pathogenic cells in the gastrointestinal tract [96, 97] . Plasmids with antibiotic-resistance genes, including genes encoding resistance to tetracycline, erythromycin, chloramphenicol, and macrolide-lincosamide-streptogramin, have been found in L. plantarum, L. fermentum, L. acidophilus, and L. reuteri strains. L. plantarum 5057 exhibited tetracycline resistance, and L. lactis was with streptomycin, tetracycline, and chloramphenicol resistances [98] [99] [100] . Although the transfer of native Lactobacillus plasmids is quite rare, there are some cases, e.g., the antibiotic-resistance plasmids from Lactococcus species could transfer
to Leuconostoc species and Pediococcus species.
With respect to the potential risks of probiotics, it is important to conduct population-based surveillance for safety concern.
Conclusions
Probiotics have the ability to restore the imbalance of intestinal microbiota and could act as both prophylactic and adjunctive therapy against candidiasis. Antifungal effect of probiotics is likely due to their interference with Candida biofilm development and hyphal differentiation. Safety may be of concern in application, as probiotic strains may, although quite rarely, cause bacteremia, fungemia, and sepsis. Well-designed RCTs are required to address these issues before the routine use of probiotics is recommended.
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